Hims & Hers Health: Investors Have a Chance to Seek Justice
Deadline: August 25, 2025
Investors who purchased shares of Hims & Hers Health between April 29, 2025, and June 23, 2025, have until August 25, 2025, to participate in a class action lawsuit. This deadline is critical for those seeking to recover losses from the company's alleged misconduct.
The Legal Action
The lawsuit alleges that Hims & Hers Health and its executives failed to disclose crucial information to investors, violating federal securities laws. The issue arose when Novo Nordisk terminated its partnership with Hims on June 23, 2025, accusing the company of:
- Selling compounded drugs under false pretenses.
- Engaging in misleading marketing practices that could endanger patients.
Market Impact
The news caused a significant drop in Hims' stock price:
- Decline: $22.24 (34.6%)
- Closing Price: $41.98 per share
- Trading Volume: Unusually high, reflecting investor reaction.
Lawsuits Filed
Two lawsuits have been initiated:
- Sookdeo v. Hims & Hers Health, Inc.
- Yaghsizian v. Hims & Hers Health, Inc. (extends the class period)
Investors wishing to lead the class action must file a petition with the court by August 25, 2025.
Next Steps for Affected Investors
Affected investors are encouraged to contact Kahn Swick & Foti, LLC for a free consultation on legal rights and potential recovery options.
- Contact:
- Phone: 1-877-515-1850 (toll-free)
- Email: lewis.kahn@ksfcounsel.com
- Website: Kahn Swick & Foti, LLC
Conclusion
This case underscores the importance of transparency in corporate practices. When companies fail to disclose critical information, investors may suffer significant financial losses. Legal actions play a vital role in holding companies accountable for their actions.